LNTH Lantheus Holdings, Inc. logo

LNTH Lantheus Holdings, Inc.

Healthcare
$103.00+9.03%ClosedMarket Cap: $6.71B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

22.46

PEG

P/B

5.50

P/S

4.34

EV/EBITDA

16.78

DCF Value

$602.54

FCF Yield

5.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

60.5%

Operating Margin

18.8%

Net Margin

18.0%

ROE

24.3%

ROA

11.9%

ROIC

10.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$377.3M$118.4M$
Q4 null$406.8M$54.1M$
FY null$1.54B$233.6M$
Q3 null$384.0M$27.8M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$103.50

Target (Median)

$102.50

Target Range

$94.00 - $115.00

2 Strong Buy9 Buy2 Hold0 Sell0 Strong Sell
Truist SecuritiesBuy
2026-05-11
MizuhoOutperform
2026-05-08
CitizensMarket Outperform
2026-05-08
Truist SecuritiesBuy
2026-03-02
CitizensMarket Outperform
2026-02-27

Trading Activity

Insider Trades

View All
Thrall James Hdirector
SellMon May 18
Pruden Gary Jdirector
SellMon May 18
Morrow Phuong Khanhdirector
SellMon May 18
McHugh Juliedirector
SellMon May 18
Maeusli Heinz Christophdirector
SellMon May 18

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

-0.08

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Peers